Meeting of Strategic Advisory Group of Experts on Immunization (SAGE)
CCV, Geneva, 6 to 8 November 2012
Declaration of interests
All 14 SAGE members participating in the meeting updated their declaration of interest ahead of the meeting. Other meeting participants do not take part in the decision-making and are thus not required to complete a declaration of interest.
Seven members reported relevant interests, which were assessed not to constitute a conflict of interest. It was concluded that all members could take part in full in all discussions. All the reported relevant interests are summarized below:
Juhani Eskola
- Receives consultancy fees for membership in Novartis Data Safety Monitoring Board for typhoid vaccines. This interest was assessed as personal, non-specific and financially insignificant*.
- Receives consultancy fees for membership in Novartis Data Safety Monitoring Board for meningococcal vaccines. This interest was assessed as personal, non-specific and financially insignificant*.
- Received in 2009 consultancy fees for participation in Novartis Pneumococcal Vaccine Advisory Group. This interest was assessed as personal, non-specific and financially insignificant*.
- His organization has a large joint research programme with GlaxoSmithKline on pneumococcal vaccines. This interest was assessed as non-personal, non-specific and financially significant*.
- Serves as the Chair of the Steering Committee for the Tuberculosis Vaccine Initiative. This interest was assessed as personal, non-specific and financially insignificant*.
Peter Figueroa
- His unit received a research grant from Merck to conduct a small clinical trial of an anti-retroviral drug on HIV for which he was the principal investigator. All the funds from this research grant went into expenses to cover the cost of the trial and he received no payment for his contribution. This interest was assessed as non-personal, non-specific and financially significant*.
Xiaofeng Liang
- Received in 2010 a travel grant from sanofi pasteur and PAREXEL to attend the Global Meningococcal Initiative's (GMI) scientific secretariat's meeting. This interest was assessed as personal, non-specific and financially insignificant*.
- His institution received funding from ten Chinese vaccine manufacturers for conducting a clinical trial on H1N1 vaccines for which he is the principal investigator. This interest was assessed as non-personal, non-specific and financially significant*.
Terence Nolan
- Received consultancy fees for participating in meetings and for data analysis and interpretation as member of Data and Safety Monitoring Board (DSMB) and Independent Data Monitoring Committee (IDMC) on Human Papilloma Virus vaccine from GlaxoSmithKline (GSK).The consultancy was ceased by the 17th October 2012. This interest was assessed as personal, non-specific and financially insignificant*.
- In the time from 2008-2012 his institution received research support for vaccine trials implemented in Australia from a number of companies (GSK, Wyeth, Novartis Vaccines, sanofi pasteur and CSL Ltd).These trials concern a number of vaccines (MenACWY, MenB, MenC, HibMenC Adult and peadiatric TIV, H1N1 and H5N1 vaccine and DTPa-Hib-hepB-IPV-MenC vaccine). This interest was assessed as non-personal, non-specific and financially significant*.
- His institution receives research support to conduct a clinical trial on paediatric Quadrivalent Influenza Vaccine from sanofi pasteur. Further travel costs and participation fees in scientific meetings were covered.. This interest was assessed as non-personal, non-specific and financially significant*.
- Received consultancy fees in 2011 from GSK for providing expert opinion to European jurisdiction in respect of clinical trial data from studies conducted by himself in the early 1990s sponsored by CSL ltd. This interest was assessed as personal, non-specific and financially insignificant*.
Kate O’Brien
- Her institution received consultancy fees from sanofi pasteur in 2010 and 2011 on pneumococcal vaccine. This interest was assessed as non-personal, non-specific and financially insignificant*.
- Her institution provided consultancy to Pfizer in 2011 on PCV13. This interest was assessed as personal, non-specific and financially insignificant*.
- Her institution provides consultancy to Merck on pneumococcal vaccine. This interest was assessed as non-personal, non-specific and financially insignificant*.
- Received consultancy fees from GSK in 2011on PCV10. This interest was assessed as personal, non-specific and financially insignificant*.
- Serves currently as member of DSMB on malaria RTSS vaccine funded by PATH-Malaria Vaccine Initiative. This interest was assessed as non-personal, non-specific and financially significant*.
- Serves currently as member of DSMB on maternal influenza vaccine funded by Bill and Melinda Gates Foundation (BMGF). This interest was assessed as personal, non-specific and financially insignificant*.
- Her institution currently receives research grants from GSK, BMGF, National Institutes on Health (NIH), and GAVI regarding pneumococcal vaccine, PCV13, PCV and rotavirus vaccine. This interest was assessed as non-personal, non-specific and financially significant*.
- Her institution received a research grant from Pfizer until 31.Oct.2012 regarding PCV13. This interest was assessed as non-personal, non-specific and financially significant*.
- Her institution received a research grant from MedImmune in 2011 regarding RSV-motavizumab. This interest was assessed as non-personal, non-specific and financially significant*.
- Her institution currently receives a research grant from BMGF regarding PCV serotype replacement. This interest was assessed as non-personal, non-specific and financially significant*.
Claire-Anne Siegrist
- Her university receives funding from sanofi pasteur, NasVax Ltd and DBV Technologies for conducting research in vaccine adjuvants and seroepidemiology of pneumococcal infections. This interest was assessed as non-personal, non-specific and financially significant*.
- Developed and owns the Viavac immunization management software destined to support Swiss health care professionals to follow the official immunization recommendations. Her ownership in the enterprise generates royalties of less than 10,000 USD per annum. This interest was assessed as personal, non-specific and financially significant*.
- Received in 2007-2010 partial travel grants from sanofi pasteur and Wyeth to attend two scientific meetings on pneumococcal vaccines. This interest was assessed as personal, non-specific and financially insignificant*.
- Until 2009, received small honoraria from GlaxoSmithKline for vaccinology training of pediatricians. This interest was assessed as personal, non-specific and financially insignificant*.
Piyanit Tharmaphornpilas
- Received in 2011 a travel grant from a joint venture of the Thai Government Pharmaceutical Organization - Merieux Biological Product to attend the Re-invigorating Immunisation Policy Implementation and Succuess: From Parent to Partner and from Broad to Engagement. This interest was assessed as personal, non-specific and financially insignificant*.
- Received in 2010 a travel grant from sanofi pasteur to attend the 8th Asia-Pacific Travel Health Conference. This interest was assessed as personal, non-specific and financially insignificant*.
- Received in 2009 an honorarium from GlaxoSmithKline for speaking in the Rotavirus Expert Forum. This interest was assessed as personal, non-specific and financially insignificant*.
- Received in 2009 a travel grant from a joint venture of the Thai Government Pharmaceutical Organization - Merieux Biological Product, to attend the Influenza Vaccines for the World conference. This interest was assessed as personal, non-specific and financially insignificant*.
* According to WHO's Guidelines for Declaration of Interests (WHO expert), an interest is considered "personal" if it generates financial or non-financial gain to the expert, such as consulting income or a patent. "Specificity" states whether the declared interest is a subject matter of the meeting or work to be undertaken. An interest has "financial significance" if the honoraria, consultancy fee or other received funding, including those received by expert's organization, from any single vaccine manufacturer or other vaccine-related company exceeds 10,000 USD in a calendar year. Likewise, a shareholding in any one vaccine manufacturer or other vaccine-related company in excess of 1,000 USD would also constitute a “significant shareholding”.